# First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes

> **NCT04880291** · PHASE1 · COMPLETED · sponsor: **Goldfinch Bio, Inc.** · enrollment: 39 (actual)

## Conditions studied

- Kidney Diseases
- Diabetic Nephropathies
- Diabetes Complications
- Diabetes Mellitus
- Endocrine System Diseases

## Interventions

- **DRUG:** GFB-024
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04880291
- **Lead sponsor:** Goldfinch Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-05
- **Primary completion:** 2022-02-08
- **Final completion:** 2022-02-08
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2022-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04880291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04880291, "First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04880291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*